Drug Profile


Alternative Names: 7F3com-2H2; Anti-IL-9 monoclonal antibody - Genaera/Ludwig; Anti-interleukin-9 monoclonal antibody - Genaera/Ludwig; MEDI-528

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genaera Corporation; Ludwig Institute for Cancer Research
  • Developer MedImmune
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 01 Oct 2011 Discontinued - Phase-II for Asthma in Argentina (SC)
  • 01 Oct 2011 Discontinued - Phase-II for Asthma in Brazil (SC)
  • 01 Oct 2011 Discontinued - Phase-II for Asthma in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top